Copyright medicaldialogues
Gland Pharma Ltd has posted a 12 per cent year-on-year rise in profit after tax (PAT) at Rs 84 crore for the quarter ended September 2025, supported by robust contributions from its CDMO subsidiary, Cenexi.In the same period last fiscal, the Hyderabad-based pharmaceutical firm had reported a PAT of Rs 163 crore.Revenue from operations grew to Rs 1,487 crore in the July–September quarter, compared to Rs 1,406 crore in the corresponding quarter of the previous fiscal, the company said."Gland Pharma delivered a strong first half of FY26, with Revenue growth of 7% and PAT up by 30% YoY. We expect stronger momentum in the second half, driven by new launches and Cenexi's recovery. Our investments in global CDMO expansion, capacity enhancement in high-end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders," Gland Pharma Executive Chairman Srinivas Sadu said.Shyamakant Giri, Chief Executive Officer of Gland Pharma, said, “For the quarter, Gland Pharma’s core business maintained its profitable growth trajectory with strong margin expansion. Encouragingly for consolidated business, we saw year-over-year improvement during the Q2 FY26 with USA growing by 10% and Europe by 16%, supported by a 21% top-line increase in Cenexi. With the current momentum, we anticipate a robust growth in the upcoming quarters.”Read also: Gland Pharma Pashamylaram facility receives GMP compliance certificate from Danish Medicines AgencyGland Pharma was established in 1978 in Hyderabad. The company has a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.Read also: USFDA approves Gland Pharma Vasopressin in 5% Dextrose RTU Injection
